First report of quetiapine use in the management of ketamine-benzodiazepine coma therapy side-effects.
Dept. of Psychiatry, Audie L. Murphy Memorial VAMC, San Antonio, TX 78229, USA. Thomas.brown5@va.gov
Angelica
A
White
Thomas M
TM
Brown
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety; D001569:Benzodiazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D059333:Central Nervous System Sensitization / Q000502:physiology; D003128:Coma / Q000139:chemically induced; D020918:Complex Regional Pain Syndromes / Q000188:drug therapy / Q000503:physiopathology; D003987:Dibenzothiazepines / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007649:Ketamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D011605:Psychoses, Substance-Induced / Q000188:drug therapy*; D000069348:Quetiapine Fumarate; D012021:Reflex, Abnormal; D007319:Sleep Initiation and Maintenance Disorders; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D007649:Ketamine